Catalog Advanced Search

Search by Categories
Search in Packages
Search by Format
Search by Type
Search by Date Range
Products are filtered by different dates, depending on the combination of live and on-demand components that they contain, and on whether any live components are over or not.
Start
End
Search by Keyword
Sort By
  • Leon Schiff SOA: Acute on Chronic Liver Failure

    Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    As HCV therapies now achieve high rates of SVR across a broad spectrum of individuals in patient care, there is a need to consider those HCV-infected persons who are not or may have difficulty accessing care or engaging in HCV therapy. Additionally, aspects related to prevention of reinfection are relevant in these difficult to reach populations. This program is targeting HCV SIG clinicians, public and global health experts as well as patient advocates with the goal of sharing expertise on how to improve the cascade of care in the “difficult to reach” populations.  

    Guadalupe Garcia-Tsao

    Dr. Garcia-Tsao is Professor of Medicine, Chief of Digestive Diseases and Program Director of the Hepatitis C Resource Center at Veteran’s Administration-Connecticut Healthcare System, as well as Director of Clinical and Translational Core at Yale Liver Center. She is a past president of AASLD. She received her M.D. and training at Universidad Nacional Autónoma de Mexico. Her primary research focus is on clinical research which focuses on cirrhosis and its complications, and she also is involved in the study of bacterial infections in cirrhosis, a complication that is often overlooked.

    Patrick S. Kamath

  • 2017 Clinical Hepatology Debrief

    Product not yet rated Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's Clinical Hepatology Debrief presented at The Liver Meeting® 2017.

    This session will provide a summary of the clinical highlights from The Liver Meeting®.

    Michael W. Fried

    Kris V. Kowdley

  • 2017 NAFLD Debrief

    Product not yet rated Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's NAFLD Debrief presented at The Liver Meeting® 2017.

    This newly added session is designed to complement the highly-regarded, Hepatitis and Clinical Hepatology Debriefs, and will review key highlights from the meeting. 

    Michael W. Fried

    Kymberly Watt

  • 2017 Hepatitis Debrief

    Product not yet rated Contains 2 Component(s) Recorded On: 10/24/2017

    AASLD's Hepatitis Debrief presented at The Liver Meeting® 2017.

    This session provides a synthesis of new data on the treatment of viral hepatitis presented at The Liver Meeting®.

    Michael W. Fried

    Paul Y. Kwo

    Dr. Kwo is currently Professor of Medicine and  Director of Hepatology at the Stanford University where he joined the faculty  in November 2016. Prior to joining the faculty at Stanford, he was  at Indiana University for   21 years where he served as the Medical Director of Liver Transplantation.  He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C.  He has won multiple awards, both at the university, local, and national level.

  • Hyman J. Zimmerman Hepatotoxicity SOA: Assessing DILI Risk in the Life Cycle of Drugs and Biologics: A Challenge for Regulatory Science

    Product not yet rated Contains 2 Component(s) Recorded On: 10/23/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    Drug-induced liver injury (DILI) remains the leading cause of acute liver failure in the U.S. This session will review methods that are used by clinical and regulatory scientists to gather information about the hepatotoxicity of a drug or biological agent, during each phase of its life cycle.  The session will highlight the diverse clinical signatures and mechanisms that underlie DILI and discuss critical challenges when analyzing drug-related risk for serious liver toxicity.

    Robert J. Fontana

    Mark I. Avigan

  • Hans Popper Basic Science SOA: Gut Microbiota and Liver

    Contains 2 Component(s) Recorded On: 10/23/2017

    AASLD's State-of-the-Art Lectures presented at The Liver Meeting® 2017.

    The intestinal microbiota and the human body have a symbiotic relationship, and a dysbalance of this delicate homeostasis can lead to disease. Liver diseases are associated with changes in the gut microbiota. Intestinal dysbiosis is characterized by bacterial overgrowth and changes in the microbiota composition. In addition, most chronic liver diseases are associated with intestinal barrier dysfunction. The contribution of intestinal dysbiosis to chronic liver disease goes beyond disruption of the intestinal barrier. Microbial metabolites are equally important for the progression of liver disease. Better understanding of host-microbial interactions will allow discovery of novel therapeutic targets in the gut microbiota, enabling new treatment options that restore the intestinal ecosystem precisely and influence liver disease. This session will review beneficial aspects of the microbiome for human health. Attendees will learn how to characterize changes of the gut microbiota associated with liver disease and their contributions to disease progression. Additionally, the session will cover modulation options of the gut microbiota to improve liver disease treatment. 

    Gavin E. Arteel

    Bernd Schnabl

  • Hepatobiliary Neoplasia SIG: HCV Therapy and HCC

    Product not yet rated Contains 8 Component(s) Recorded On: 10/23/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    This program provides a timely review of the mechanistic and clinical information relevant to HCC occurring in HCV by addressing the relevance of the problem and treatment effects. The program will also discuss key basic concepts with relevance to HCC in HCV.

    Gregory J. Gores

    Augusto Villanueva

    Augusto Villanueva is Assistant Professor in the Liver Cancer Program (Icahn School of Medicine at Mount Sinai, New York). He received his medical degree from the University of Santiago de Compostela (Spain), and he is board certified in Gastroenterology and Hepatology (Spain). In 2005, he joined the Division of Liver Diseases at Mount Sinai Hospital (New York) as a research fellow and was involved in different translational research projects focused on the molecular pathogenesis of hepatocellular carcinoma (HCC). In 2008, he obtained his PhD and received the Sheila Sherlock Fellowship from EASL to join the Liver Cancer Translational Research Laboratory of the BCLC Group, Barcelona (Spain). In 2010, he became the Scientific Manager of the HEPTROMIC consortium, a research initiative funded by the European Commission aimed at identifying genomic prognostic predictors and oncogenic drivers in HCC.

    In 2013, he joined the Institute of Liver Studies at King’s College (London), as a Senior Lecturer and Consultant Hepatologist where he served as co-leader of the HCC Clinic and Multidisciplinary Tumor Board. In 2014, he started his position at the Icahn School of Medicine at Mount Sinai with the goal of developing novel minimally invasive biomarkers using liquid biopsy and studying the impact of intratumor heterogeneity in HCC. He has more than 100 publications (10,000 citations, H-index 44) including articles in N Engl J MedNat GenetNat BiotechGastroenterology, HEPATOLOGY, J HepatolJ Clin InvestOncogene, etc. He wrote more than fifteen book chapters and edited a book on resistance to targeted therapies in HCC. He served as Associate Editor for J Hepatol (2014-2019) and Liver Cancer (2012-present).

    Hashem B. El-Serag

    Nathalie G. Carrie

    Michael D. Leise

    Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester.  He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.

    Maria Reig

    Amit G. Singal

    Dr. Singal completed his GI and transplant hepatology fellowships at the University of Michigan and is currently an Associate Professor of Medicine at UT Southwestern Medical Center in Dallas. He serves as Clinical Chief of Hepatology and Medical Director of the UT Southwestern and Parkland Memorial Liver Tumor programs. He has over 75 peer-reviewed publications, with the majority examining the hepatocellular carcinoma screening process, from risk assessment to early detection to treatment. 

    Laura M. Kulik

  • HCV 2017 Treatment Symposium

    Product not yet rated Contains 5 Component(s) Recorded On: 10/23/2017

    AASLD's Special Interest Group (SIG) Sessions presented at The Liver Meeting® 2017.

    This program will include discussions of recently approved regimens and challenging patient populations.  The emphasis in these lectures will be on clinical knowledge and application to individual patient management decisions, the AASLD-IDSA Guidance Panel treatment recommendations, and global perspectives on disease eradication strategies.

    Andrew J. Muir

    Dr. Andrew Muir is a gastroenterologist whose research activities are focused on developing innovative treatments for a variety of liver diseases. Through his work at the Durham Veterans Administration Medical Center, Dr. Muir has participated in the development programs of many of the direct acting antiviral agents that have revolutionized hepatitis C care. He assumed the leadership of the Gastroenterology and Hepatology Research program at DCRI in 2010 and has expanded the research portfolio to include other liver disorders and gastroenterology outcomes. His particular interests include viral hepatitis, primary sclerosing cholangitis, and liver transplantation. He also has a longstanding interest in healthcare disparities.

    Susanna Naggie

    Philippa Easterbrook

    Paul Y. Kwo

    Dr. Kwo is currently Professor of Medicine and  Director of Hepatology at the Stanford University where he joined the faculty  in November 2016. Prior to joining the faculty at Stanford, he was  at Indiana University for   21 years where he served as the Medical Director of Liver Transplantation.  He has distinguished himself in the field of chronic Hepatitis C and has a large practice devoted to current and novel therapies for the treatment of Hepatitis C.  He has won multiple awards, both at the university, local, and national level.

    Paul J. Pockros

  • Advances for Practitioners: Cholestatic and Autoimmune Liver Disease

    Product not yet rated Contains 3 Component(s) Recorded On: 10/23/2017

    AASLD's Advances for Practitioners presented at The Liver Meeting® 2017.

    This session will highlight recent key studies in the field of cholestatic and autoimmune liver diseases. Speakers will review data on new therapies for the treatment of PBC and discuss the role of risk stratification in the management of this disease. Additionally, recent studies evaluating new biomarkers and surveillance strategies in PSC will be reviewed to determine their usefulness and applicability. Finally, the session will evaluate the evidence underlying the use of specific second line therapies in autoimmune hepatitis and a treatment algorithm will be proposed.

    Christopher L. Bowlus

    Dr. Christopher Bowlus obtained his medical degree at St. Louis University and completed his postgraduate training at University of California Davis and Yale University. Dr. Bowlus is Professor of Medicine and Chief of the Division of Gastroenterology and Hepatology at UC Davis. Dr. Bowlus conducts clinical and translational research in autoimmune liver diseases including primary biliary cholangitis and primary sclerosing cholangitis.

    Christoph Schramm

    John M. Vierling

  • 2017 Global Forum: The Global Burden of Non-alcoholic Fatty Liver Disease

    Product not yet rated Contains 7 Component(s) Recorded On: 10/23/2017

    AASLD's Global Forum presented at The Liver Meeting® 2017.

    NAFLD affects 24% of the adult population worldwide. Additionally, about 10% of children and adolescents may have NAFLD. NAFLD is closely associated with type 2 diabetes and obesity. A proportion of subjects with NAFLD and non-alcoholic steatohepatitis (NASH) can develop progressive liver disease, cirrhosis and liver cancer. There are extensive efforts to develop non-invasive tests for NASH. Although no approved therapeutic options for NASH are yet available, a large number of clinical trials are underway. This forum will review, in all pertinent regions of the world, the current state of NAFLD with regard to its clinical and epidemiologic burden and discuss knowledge gaps, unmet needs and current clinical practice.  A secondary focus will be to foster global collaboration and exchange to reach a common objective to improve patient outcomes, decrease disease burden by NAFLD and how to prevent and treat NAFLD throughout the world.

    Zobair M. Younossi

    Frank Tacke

    Barjesh C. Sharma

    Marco Arrese

    Hisham R. El Khayat

    Miriam B. Vos